Antimicrobial dosing in special populations US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Antimicrobial dosing in special populations. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Antimicrobial dosing in special populations US Medical PG Question 1: A 13-year-old boy presents to his pediatrician with a 1-day history of frothy brown urine. He says that he believes he had strep throat some weeks ago, but he was not treated with antibiotics as his parents were worried about him experiencing harmful side effects. His blood pressure is 148/96 mm Hg, heart rate is 84/min, and respiratory rate is 15/min. Laboratory analysis is notable for elevated serum creatinine, hematuria with RBC casts, and elevated urine protein without frank proteinuria. His antistreptolysin O titer is elevated, and he is subsequently diagnosed with post-streptococcal glomerulonephritis (PSGN). His mother is distraught regarding the diagnosis and is wondering if this could have been prevented if he had received antibiotics. Which of the following is the most appropriate response?
- A. Antibiotic therapy decreases the severity of PSGN.
- B. Once a patient is infected with a nephritogenic strain of group A streptococcus, the development of PSGN cannot be prevented. (Correct Answer)
- C. Antibiotic therapy only prevents PSGN in immunosuppressed patients.
- D. Antibiotic therapy may decrease the risk of developing PSGN.
- E. Antibiotic therapy can prevent the development of PSGN.
Antimicrobial dosing in special populations Explanation: ***Correct: Once a patient is infected with a nephritogenic strain of group A streptococcus, the development of PSGN cannot be prevented.***
- PSGN is an **immune-mediated disease** that occurs after a Group A Streptococcus (GAS) infection. Since the immune response has already been initiated, antibiotics given *after* the infection has occurred will not alter the risk of developing PSGN.
- Antibiotics are effective at treating the infection itself, but their role in preventing PSGN is primarily related to **eradication of the strep organism** to prevent spread to others and to reduce the risk of acute rheumatic fever.
*Incorrect: Antibiotic therapy decreases the severity of PSGN.*
- Antibiotic therapy for an established GAS infection does not reduce the **severity** or alter the clinical course of PSGN once it has developed.
- The kidney damage in PSGN is due to an immune response, not the direct bacterial infection, so antibiotics have no direct impact on the **glomerular inflammation**.
*Incorrect: Antibiotic therapy only prevents PSGN in immunosuppressed patients.*
- This statement is incorrect as there is **no evidence** that antibiotic therapy selectively prevents PSGN in immunosuppressed patients.
- The immune pathogenesis of PSGN means that antibiotics are ineffective at preventing it, regardless of the patient's **immune status**.
*Incorrect: Antibiotic therapy may decrease the risk of developing PSGN.*
- While antibiotics are crucial for preventing acute rheumatic fever, they do not consistently reduce the risk of developing PSGN once a GAS infection has occurred.
- The **time window** for effective prevention of PSGN with antibiotics is very narrow or non-existent, as the immune cascade typically starts during the infection.
*Incorrect: Antibiotic therapy can prevent the development of PSGN.*
- This statement is generally incorrect. Unlike acute rheumatic fever where prompt antibiotic treatment can prevent its development, PSGN is believed to be preventable only if the **nephritogenic strain of GAS** is eradicated *before* the immune response leading to glomerulonephritis is initiated.
- In most real-world scenarios, by the time a patient presents with symptoms of a GAS infection, the immune processes that could lead to PSGN are already underway or inevitable given the specific strain involved.
Antimicrobial dosing in special populations US Medical PG Question 2: A 62-year-old man comes to the physician for a follow-up examination. One month ago, therapy with lisinopril was initiated for treatment of hypertension. His blood pressure is 136/86 mm Hg. Urinalysis shows a creatinine clearance of 92 mL/min. The patient's serum creatinine concentration is most likely closest to which of the following values?
- A. 1.7 mg/dL
- B. 1.1 mg/dL (Correct Answer)
- C. 2.0 mg/dL
- D. 1.4 mg/dL
- E. 2.3 mg/dL
Antimicrobial dosing in special populations Explanation: ***1.1 mg/dL***
- For a 62-year-old man with a **creatinine clearance of 92 mL/min**, the serum creatinine can be estimated using the **Cockcroft-Gault relationship**.
- With CrCl of 92 mL/min (near-normal for age), the baseline serum creatinine would be approximately **0.9-1.0 mg/dL** for a typical male patient.
- **Lisinopril (ACE inhibitor)** commonly causes a **mild increase in serum creatinine (10-20%)** due to reduced efferent arteriolar tone, which is acceptable if <30% increase and creatinine clearance remains adequate.
- Therefore, **1.1 mg/dL** represents the expected value: baseline creatinine consistent with CrCl of 92 mL/min plus the typical mild ACE inhibitor-induced elevation.
*1.4 mg/dL*
- A serum creatinine of **1.4 mg/dL** would be inconsistent with a creatinine clearance of **92 mL/min** in this patient.
- Using the Cockcroft-Gault formula for a 62-year-old male, a creatinine of 1.4 mg/dL would correspond to a **CrCl of approximately 65-70 mL/min**, not 92 mL/min.
- This would represent a more significant decrease in GFR than is present in this patient.
*1.7 mg/dL*
- A serum creatinine of **1.7 mg/dL** is far too high for a creatinine clearance of **92 mL/min**.
- This level would correspond to a **CrCl of approximately 50-55 mL/min** in a 62-year-old male, indicating **moderate renal impairment**.
- Such an elevation with ACE inhibitors would warrant investigation for **bilateral renal artery stenosis** or other significant renal pathology.
*2.0 mg/dL*
- A serum creatinine of **2.0 mg/dL** would indicate **significant renal dysfunction** with an estimated CrCl of approximately **40-45 mL/min**, not the 92 mL/min observed.
- This degree of elevation is incompatible with the measured creatinine clearance.
- Would suggest **acute kidney injury** or **severe bilateral renal artery stenosis** and require immediate ACE inhibitor discontinuation.
*2.3 mg/dL*
- A serum creatinine of **2.3 mg/dL** indicates **severe renal impairment** with an estimated CrCl well below 40 mL/min.
- This is completely incompatible with the measured **creatinine clearance of 92 mL/min**.
- Would represent **acute kidney injury** requiring urgent evaluation and medication adjustment.
Antimicrobial dosing in special populations US Medical PG Question 3: A 26-year-old man comes to the emergency department because of a 1-week history of worsening fatigue, nausea, and vomiting. Six weeks ago, he was diagnosed with latent tuberculosis and appropriate low-dose pharmacotherapy was initiated. Physical examination shows right upper quadrant tenderness and scleral icterus. Laboratory studies show elevated aminotransferases. Impaired function of which of the following pharmacokinetic processes is the most likely explanation for this patient's symptoms?
- A. Acetylation (Correct Answer)
- B. Glucuronidation
- C. Hydrolysis
- D. Sulfation
- E. Reduction
Antimicrobial dosing in special populations Explanation: ***Acetylation***
- This patient is exhibiting symptoms of **hepatotoxicity** (fatigue, nausea, vomiting, RUQ tenderness, scleral icterus, elevated aminotransferases) after starting low-dose pharmacotherapy for latent tuberculosis. The most common drug used for latent TB is **isoniazid**, which is primarily metabolized by **N-acetylation**.
- Impaired acetylation, particularly in **slow acetylators**, can lead to higher plasma concentrations of isoniazid and its toxic metabolites, increasing the risk of **drug-induced liver injury**.
*Glucuronidation*
- **Glucuronidation** is a Phase II metabolic pathway that conjugates drugs with **glucuronic acid** to increase water solubility and facilitate excretion.
- While important for the metabolism of many drugs and endogenous substances (e.g., bilirubin), it is not the primary mechanism of metabolism or the main pathway implicated in the hepatotoxicity of **isoniazid**.
*Hydrolysis*
- **Hydrolysis** is a chemical reaction in which water is used to break down a compound, often involving ester or amide bonds.
- This process is not the primary metabolic pathway for **isoniazid**, nor is impaired hydrolysis a common cause of its hepatotoxicity.
*Sulfation*
- **Sulfation** is a Phase II metabolic reaction that conjugates drugs with a **sulfate group**, typically for detoxification and excretion.
- While various drugs undergo sulfation, it is not the dominant metabolic pathway for **isoniazid**, and impaired sulfation is not typically associated with isoniazid-induced hepatotoxicity.
*Reduction*
- **Reduction** reactions involve the gain of electrons or hydrogen atoms, or the loss of oxygen, and are part of drug metabolism for certain compounds.
- However, reduction is not the primary clearance mechanism for **isoniazid**, and abnormal reduction is not commonly implicated in its hepatotoxic effects.
Antimicrobial dosing in special populations US Medical PG Question 4: A 52-year-old man presents to his physician after his routine screening revealed that he has elevated liver enzymes. He complains of occasional headaches during the past year, but otherwise feels well. The patient reports that he was involved in a serious car accident in the 1980s. He does not smoke or drink alcohol. He has no history of illicit intravenous drug use. He does not currently take any medications and has no known allergies. His father had a history of alcoholism and died of liver cancer. The patient appears thin. His temperature is 37.8°C (100°F), pulse is 100/min, and blood pressure is 110/70 mm Hg. The physical examination reveals no abnormalities. The laboratory test results show the following:
Complete blood count
Hemoglobin 14 g/dL
Leukocyte count 10,000/mm3
Platelet count 146,000/mm3
Comprehensive metabolic profile
Glucose 150 mg/dL
Albumin 3.2 g/dL
Total bilirubin 1.5 mg/dL
Alkaline phosphatase 75 IU/L
AST 95 IU/L
ALT 73 IU/L
Other lab tests
HIV negative
Hepatitis B surface antigen negative
Hepatitis C antibody positive
HCV RNA positive
HCV genotype 1
A liver biopsy is performed and shows mononuclear infiltrates localized to portal tracts that reveal periportal hepatocyte necrosis. Which of the following is the most appropriate next step in management?
- A. Peginterferon alpha therapy
- B. Interferon and ribavirin therapy
- C. Sofosbuvir and ledipasvir therapy (Correct Answer)
- D. Tenofovir and entecavir therapy
- E. Tenofovir and velpatasvir therapy
Antimicrobial dosing in special populations Explanation: ***Sofosbuvir and ledipasvir therapy***
- This patient has chronic **Hepatitis C (HCV) infection** (HCV antibody positive, HCV RNA positive). **Sofosbuvir/ledipasvir** is an effective **direct-acting antiviral (DAA)** regimen for **genotype 1 HCV**, which is indicated for treatment-naïve patients without cirrhosis.
- The liver biopsy findings of **mononuclear infiltrates** and **periportal necrosis** confirm active hepatitis and the need for antiviral treatment to prevent progression to cirrhosis.
*Peginterferon alpha therapy*
- **Peginterferon alpha** was historically used for HCV, but its use has largely been replaced by **DAAs** due to significant side effects and lower efficacy.
- This therapy is associated with numerous adverse effects, including **flu-like symptoms**, **depression**, and **bone marrow suppression**.
*Interferon and ribavirin therapy*
- This combination was a standard treatment for HCV before the advent of DAAs, but it is associated with a high burden of **side effects** like **hemolytic anemia** (from ribavirin) and **flu-like symptoms** (from interferon).
- Given the availability of highly effective and well-tolerated DAAs, this regimen is no longer considered first-line for chronic HCV.
*Tenofovir and entecavir therapy*
- **Tenofovir** and **entecavir** are antiviral medications primarily used for the treatment of **chronic Hepatitis B (HBV) infection**.
- This patient's **Hepatitis B surface antigen is negative**, ruling out chronic HBV infection as the primary issue requiring these specific drugs.
*Tenofovir and velpatasvir therapy*
- While **velpatasvir** is a DAA used for HCV, its combination with **tenofovir** is not a standard HCV treatment for genotype 1.
- **Tenofovir** is primarily an anti-HBV drug; for HCV, velpatasvir is typically combined with **sofosbuvir** (as in Epclusa) for pan-genotypic coverage.
Antimicrobial dosing in special populations US Medical PG Question 5: A 49-year-old woman presents to the family medicine clinic with concerns about her weight. She has been constantly gaining weight for a decade now as she has not been able to control her diet. She has tried exercising but says that she is too lazy for this method of weight loss to work. Her temperature is 37° C (98.6° F), respirations are 15/min, pulse is 67/min, and blood pressure is 122/88 mm Hg. Her BMI is 30. Her labs from her past visit show:
Fasting blood glucose: 149 mg/dL
Glycated hemoglobin (HbA1c): 9.1%
Triglycerides: 175 mg/dL
LDL-Cholesterol: 102 mg/dL
HDL-Cholesterol: 35 mg/dL
Total Cholesterol: 180 mg/dL
Serum creatinine: 1.0 mg/dL
BUN: 12 mg/dL
Serum:
Albumin: 4.2 gm/dL
Alkaline phosphatase: 150 U/L
Alanine aminotransferase: 76 U/L
Aspartate aminotransferase: 88 U/L
After discussing the long term issues that will arise if her health does not improve, she agrees to modify her lifestyle and diet. Which of the following would be the best pharmacotherapy for this patient?
- A. Insulin
- B. Metformin (Correct Answer)
- C. Dietary modification alone
- D. Sitagliptin
- E. Glipizide
Antimicrobial dosing in special populations Explanation: ***Metformin***
- This patient has newly diagnosed **type 2 diabetes mellitus** (Fasting blood glucose 149 mg/dL, HbA1c 9.1%) in the setting of obesity (BMI 30). **Metformin** is the **first-line pharmacotherapy** for type 2 diabetes due to its efficacy, favorable safety profile, and potential for weight neutrality or modest weight loss.
- Metformin works by **decreasing hepatic glucose production**, decreasing intestinal glucose absorption, and increasing insulin sensitivity.
*Insulin*
- While insulin is highly effective in lowering blood glucose, it is typically reserved for patients with **very high HbA1c** (often >10%), **symptomatic hyperglycemia**, or those who have failed oral pharmacotherapy, it can also cause **weight gain**.
- Initiating insulin as first-line therapy can be overly aggressive and may lead to **hypoglycemia** in patients who can respond to oral agents.
*Dietary modification alone*
- Although **lifestyle changes** (diet and exercise) are crucial and can be remarkably effective, this patient's **HbA1c of 9.1%** indicates that **monotherapy with diet and exercise alone is insufficient** to achieve glycemic control.
- Pharmacotherapy is generally recommended for HbA1c levels **above 7.5%**, even with a commitment to lifestyle changes.
*Sitagliptin*
- **Sitagliptin** is a **DPP-4 inhibitor** that increases insulin secretion and decreases glucagon secretion in a glucose-dependent manner.
- It is often considered a **second-line agent** or an add-on therapy, as its HbA1c-lowering effect is generally less potent than metformin.
*Glipizide*
- **Glipizide** is a **sulfonylurea** that works by stimulating insulin release from pancreatic beta cells.
- It can cause **weight gain** and has a significant risk of **hypoglycemia**, making it a less favorable first-line agent, especially in an obese patient, compared to metformin.
Antimicrobial dosing in special populations US Medical PG Question 6: A researcher is investigating the effects of a new antihypertensive medication on renal physiology. She gives a subject a dose of the new medication, and she then collects plasma and urine samples. She finds the following: Hematocrit: 40%; Serum creatinine: 0.0125 mg/mL; Urine creatinine: 1.25 mg/mL. Urinary output is 1 mL/min. Renal blood flow is 1 L/min. Based on the above information and approximating that the creatinine clearance is equal to the GFR, what answer best approximates filtration fraction in this case?
- A. 10%
- B. 17% (Correct Answer)
- C. 33%
- D. 50%
- E. 25%
Antimicrobial dosing in special populations Explanation: ***17%***
- First, calculate **GFR** using the creatinine clearance formula: GFR = (Urine creatinine × Urinary output) / Serum creatinine = (1.25 mg/mL × 1 mL/min) / 0.0125 mg/mL = **100 mL/min**.
- Next, calculate **Renal Plasma Flow (RPF)** from Renal Blood Flow (RBF) and Hematocrit: RPF = RBF × (1 - Hematocrit) = 1000 mL/min × (1 - 0.40) = **600 mL/min**.
- Finally, calculate **Filtration Fraction (FF)** = GFR / RPF = 100 mL/min / 600 mL/min = 0.1667 = **16.7%, which approximates to 17%**.
- This is the correct answer based on the physiological calculations and represents a normal filtration fraction.
*10%*
- This would correspond to a filtration fraction of 0.10, which would require either a GFR of 60 mL/min (lower than calculated) or an RPF of 1000 mL/min (higher than calculated).
- This value is too low given the provided parameters and doesn't match the calculation from the given data.
*25%*
- This value would suggest FF = 0.25, requiring a GFR of 150 mL/min with the calculated RPF of 600 mL/min.
- This is higher than the calculated GFR of 100 mL/min and doesn't match the given creatinine values.
*33%*
- This would imply FF = 0.33, requiring a GFR of approximately 200 mL/min with RPF of 600 mL/min.
- This is significantly higher than the calculated GFR and would represent an abnormally elevated filtration fraction.
*50%*
- A filtration fraction of 50% is unphysiologically high and would indicate severe pathology.
- This would require a GFR of 300 mL/min with the calculated RPF, which is impossible given the provided creatinine clearance data.
Antimicrobial dosing in special populations US Medical PG Question 7: An investigator is studying a strain of bacteria that retains a blue color after crystal violet dye and acetone are applied. The bacteria are inoculated in a petri dish containing hypotonic saline. After the addition of an antibiotic, the bacteria swell and rupture. This antibiotic most likely belongs to which of the following classes?
- A. Macrolide
- B. Cephalosporin (Correct Answer)
- C. Sulfonamide
- D. Fluoroquinolone
- E. Tetracycline
Antimicrobial dosing in special populations Explanation: ***Cephalosporin***
- This scenario describes a **Gram-positive bacterium** (retains blue color) which, after antibiotic treatment, swells and lyses in a hypotonic solution. This indicates a defect in the **peptidoglycan cell wall**.
- **Cephalosporins** are **β-lactam antibiotics** that inhibit bacterial cell wall synthesis by interfering with **peptidoglycan cross-linking**, leading to osmotic lysis in hypotonic environments.
*Macrolide*
- Macrolides like **azithromycin** and **erythromycin** inhibit bacterial **protein synthesis** by binding to the 50S ribosomal subunit.
- They do not directly target the cell wall, so they would not cause immediate osmotic lysis in this manner.
*Sulfonamide*
- Sulfonamides inhibit bacterial **folic acid synthesis** by acting as a competitive inhibitor of dihydropteroate synthase, disrupting DNA and RNA production.
- Their mechanism of action does not involve direct cell wall disruption or osmotic lysis.
*Fluoroquinolone*
- Fluoroquinolones interfere with bacterial **DNA replication and transcription** by inhibiting **DNA gyrase** and **topoisomerase IV**.
- This class of antibiotics does not primarily target the cell wall, and therefore would not lead to prompt osmotic swelling and rupture.
*Tetracycline*
- Tetracyclines inhibit bacterial **protein synthesis** by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA.
- They do not affect the cell wall, so they would not cause the observed osmotic lysis.
Antimicrobial dosing in special populations US Medical PG Question 8: An experimental drug, ES 62, is being studied. It prohibits the growth of vancomycin-resistant Staphylococcus aureus. It is highly lipid-soluble. The experimental design is dependent on a certain plasma concentration of the drug. The target plasma concentration is 100 mmol/dL. Which of the following factors is most important for calculating the appropriate loading dose?
- A. Volume of distribution (Correct Answer)
- B. Half-life of the drug
- C. Therapeutic index
- D. Clearance of the drug
- E. Rate of administration
Antimicrobial dosing in special populations Explanation: **Volume of distribution**
- The **loading dose** is primarily determined by the desired **plasma concentration** and the **volume of distribution (Vd)**, as it reflects how extensively a drug is distributed in the body.
- The formula for loading dose is: Loading Dose = (Target Plasma Concentration × Vd).
*Half-life of the drug*
- The **half-life** is crucial for determining the **dosing interval** and the time it takes to reach **steady-state concentrations**, not the initial loading dose.
- It reflects the rate at which the drug is eliminated from the body.
*Therapeutic index*
- The **therapeutic index** is a measure of a drug's relative safety, indicating the ratio between the **toxic dose** and the **effective dose**.
- While important for drug safety, it does not directly determine the magnitude of the loading dose itself.
*Clearance of the drug*
- **Clearance** is the rate at which the drug is removed from the body and is a primary determinant of the **maintenance dose** required to sustain a desired plasma concentration.
- It does not directly calculate the initial loading dose needed to achieve an immediate target concentration.
*Rate of administration*
- The **rate of administration** (e.g., infusion rate) primarily influences how quickly the drug reaches its target concentration, but not the total quantity of drug needed for the initial loading dose.
- It affects the kinetics of how the loading dose achieves the target concentration, rather than defining the dose amount.
Antimicrobial dosing in special populations US Medical PG Question 9: A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?
- A. Phase 0
- B. Phase III
- C. Phase V
- D. Phase II
- E. Phase I (Correct Answer)
Antimicrobial dosing in special populations Explanation: ***Phase I***
- **Phase I clinical trials** involve a small group of healthy volunteers (typically 20-100) to primarily assess **drug safety**, determine a safe dosage range, and identify side effects.
- The main goal is to establish the **maximum tolerated dose (MTD)** and evaluate the drug's pharmacokinetic and pharmacodynamic profiles.
*Phase 0*
- **Phase 0 trials** are exploratory studies conducted in a very small number of subjects (10-15) to gather preliminary data on a drug's **pharmacodynamics and pharmacokinetics** in humans.
- They involve microdoses, not intended to have therapeutic effects, and thus cannot determine toxicity or MTD.
*Phase III*
- **Phase III trials** are large-scale studies involving hundreds to thousands of patients to confirm the drug's **efficacy**, monitor side effects, compare it to standard treatments, and collect information that will allow the drug to be used safely.
- These trials are conducted after safety and initial efficacy have been established in earlier phases.
*Phase V*
- "Phase V" is not a standard, recognized phase in the traditional clinical trial classification (Phase 0, I, II, III, IV).
- This term might be used in some non-standard research contexts or for post-marketing studies that go beyond Phase IV surveillance, but it is not a formal phase for initial drug development.
*Phase II*
- **Phase II trials** involve several hundred patients with the condition the drug is intended to treat, focusing on **drug efficacy** and further evaluating safety.
- While safety is still monitored, the primary objective shifts to determining if the drug works for its intended purpose and at what dose.
Antimicrobial dosing in special populations US Medical PG Question 10: A 22-year-old female with no past medical history presents to her primary care physician with a 3-day history of knee pain. She denies any recent injury or trauma. On physical examination her knee is warm, erythematous, and has diminished range of movement. The patient reports having multiple sexual partners over the last year and does not use protection regularly. Her blood pressure is 124/85 mmHg, heart rate is 76/min, and temperature is 38.3℃ (101.0℉). A joint aspiration is performed and a growth of gram-negative diplococci is noted on bacterial culture. What is the treatment of choice for this patient's condition?
- A. Vancomycin monotherapy
- B. Fluoroquinolones
- C. Nafcillin monotherapy and joint aspiration
- D. Oxacillin and ceftriaxone
- E. Ceftriaxone monotherapy and joint aspiration (Correct Answer)
Antimicrobial dosing in special populations Explanation: ***Ceftriaxone monotherapy and joint aspiration***
- The patient's presentation with **acute monoarthritis**, fever, and **gram-negative diplococci** on joint culture is highly suggestive of **gonococcal arthritis**. Intravenous ceftriaxone is the treatment of choice for disseminated gonococcal infection.
- While joint aspiration confirms the diagnosis and can relieve pressure, definitive treatment requires systemic antibiotics to clear the infection.
*Vancomycin monotherapy*
- **Vancomycin** is primarily effective against **gram-positive bacteria**, particularly MRSA, and would not adequately cover the gram-negative diplococci found in this case.
- Using vancomycin alone would leave the patient's gonococcal infection untreated, potentially leading to worsening of symptoms or complications.
*Fluoroquinolones*
- While some fluoroquinolones have activity against *Neisseria gonorrhoeae*, **widespread resistance** to this class of antibiotics has emerged, making them an unreliable choice for empiric or first-line treatment of gonococcal infections.
- The CDC no longer recommends fluoroquinolones for gonococcal infections due to high rates of resistance.
*Nafcillin monotherapy and joint aspiration*
- **Nafcillin** is a narrow-spectrum penicillin effective primarily against **methicillin-sensitive *Staphylococcus aureus*** and other gram-positive organisms.
- It would not provide appropriate coverage for the **gram-negative diplococci** identified in this patient's joint fluid.
*Oxacillin and ceftriaxone*
- While **ceftriaxone** is appropriate, the addition of **oxacillin** (another anti-staphylococcal penicillin) would be unnecessary.
- Oxacillin is primarily used for gram-positive infections and would not add benefit against **gonococcal arthritis**, increasing the risk of adverse effects without improving efficacy.
More Antimicrobial dosing in special populations US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
